CGS.AX
Cogstate Limited
ASXAUDEQUITY
Healthcare
DELAYED
Last price
3.10
▲ 0.06 (1.97%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
3.09
Prev close
3.04
Day high
3.23
Day low
3.04
Volume
333.60K
Market cap
$526.75M
P/E (TTM)
34.44
52W range
1.65 – 3.23
Day trading desk
Gap from prior close
+0.32%
Prior close 3.08
VWAP
3.11
-0.17% from price
Relative volume
0.80×
Normal
Session range
7.67%
3.00 – 3.23
Position in range
43%
Mid range
ATR (14D)
0.13
4.33% of price
Prior day high
3.12
PDH
Prior day low
2.95
PDL
Bid / ask spread
—
Quote not published
Session volume
311.52K
Avg 391.48K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+10.71%
+12.1%
1M
+20.16%
+16.4%
3M
+18.77%
+15.7%
6M
+42.20%
+31.1%
YTD
+37.17%
+24.9%
1Y
+73.67%
+53.7%
3Y
+112.33%
+38.2%
5Y
+85.63%
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CGS.AX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
69.98M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 30, 26 | Colite (R) Divisional Officer |
— | 88.56K | — | Direct |
| May 20, 26 | Wenn (Kim) Independent Non-Executive Director |
BUY | 4.03K | $7.22K | Direct |
| Dec 15, 25 | Wenn (Kim) Independent Non-Executive Director |
BUY | 10.18K | $14.78K | Direct |
| Oct 17, 25 | O'Connor (Bradley John) Chief Executive Officer |
— | 61.07K | — | Direct |
| Sep 3, 25 | Mohs (Richard) Director (Non-Executive) |
OTHER | 13.00K | $9.61K | Direct |
| Aug 29, 25 | O'Connor (Bradley John) Chief Executive Officer |
BUY | 50.33K | $57.20K | Direct |
| Jul 9, 25 | O'Connor (Bradley John) Chief Executive Officer |
EXERCISE | 850.50K | $434.61K | Direct |
| Jun 30, 25 | Ventola (P) Other Executive |
— | 404.20K | — | Direct |
| Sep 10, 24 | O'Connor (Bradley John) Chief Executive Officer |
— | 1.00M | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
Colite (R) |
Divisional Officer | 275.27K | Other |
Mohs (Richard) |
Director (Non-Executive) | 80.00K | Other |
O'Connor (Bradley John) |
Chief Executive Officer | 6.40M | Other |
Ventola (P) |
Other Executive | 404.20K | Other |
Wenn (Kim) |
Independent Non-Executive Director | 26.80K | Purchase |
Fundamentals
Market cap$526.75M
Enterprise value$494.75M
Revenue (TTM)$60.86M
Gross profit$35.02M
EBITDA$17.46M
Net income$11.90M
EPS (TTM)$0.09
Free cash flow$-413.88K
Total cash$34.78M
Total debt$359.18K
Book value / share$0.48
Shares outstanding169.92M
Float120.10M
Short % of float—
Dividend yield1.29%
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E34.44
Forward P/E20.22
PEG ratio—
Price / sales—
Price / book6.47
EV / revenue8.13
EV / EBITDA28.34
Gross margin57.53%
Operating margin28.31%
Profit margin19.54%
Return on equity22.41%
Return on assets12.57%
Debt / equity0.62
Current ratio3.54
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $58.37M | $50.81M | $43.43M | $40.45M | — | +14.9% |
| Operating revenue | $58.37M | $50.81M | $43.43M | $40.45M | — | +14.9% |
| Cost of revenue | $24.49M | $20.12M | $18.72M | $18.86M | — | +21.7% |
| Gross profit | $33.88M | $30.69M | $24.71M | $21.59M | — | +10.4% |
| Selling, general & admin | $12.90M | $12.86M | $13.63M | $14.49M | — | +0.3% |
| Total operating expense | $21.68M | $19.89M | $18.53M | $19.34M | — | +9.0% |
| Operating income | $12.20M | $10.80M | $6.17M | $2.25M | — | +13.0% |
| Net interest income | $864.04K | $848.88K | -$51.22K | $632.86K | — | +1.8% |
| Pre-tax income | $16.11M | $13.91M | $7.10M | $3.03M | — | +15.9% |
| Tax provision | $4.22M | $3.76M | $1.65M | -$542.62K | — | +12.1% |
| Net income | $11.90M | $10.14M | $5.45M | $3.57M | — | +17.3% |
| Net income to common | $11.90M | $10.14M | $5.45M | $3.57M | — | +17.3% |
| Basic EPS | — | 0.06 | 0.03 | 0.02 | 0.04 | — |
| Diluted EPS | — | 0.06 | 0.03 | 0.02 | 0.04 | — |
| EBIT | $16.13M | $13.98M | $7.15M | $3.09M | — | +15.3% |
| EBITDA | $19.22M | $16.93M | $9.89M | $5.69M | — | +13.5% |
| Basic shares | — | 171.29M | 171.81M | 173.44M | 172.77M | — |
| Diluted shares | — | 174.01M | 173.01M | 176.62M | 176.93M | — |
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $34.78M | $35.56M | $30.12M | $28.68M | — | -2.2% |
| Cash & short-term investments | $34.78M | $35.56M | $30.12M | $28.68M | — | -2.2% |
| Accounts receivable | $19.96M | $12.81M | $10.11M | $7.62M | — | +55.9% |
| Total current assets | $59.01M | $50.30M | $43.46M | $38.78M | — | +17.3% |
| Property, plant & equipment | $762.37K | $790.80K | $976.30K | $596.39K | — | -3.6% |
| Goodwill & intangibles | $14.08M | $10.81M | $10.48M | $11.11M | — | +30.2% |
| Total assets | $78.06M | $64.77M | $57.84M | $54.07M | — | +20.5% |
| Total current liabilities | $16.68M | $13.34M | $12.69M | $12.29M | — | +25.0% |
| Current debt | — | — | $109.43K | $115.90K | $183.35K | — |
| Total debt | $359.18K | $469.92K | $672.72K | $378.89K | — | -23.6% |
| Total liabilities | $19.79M | $16.88M | $17.03M | $16.49M | — | +17.3% |
| Retained earnings | $5.44M | $5.76M | $2.34M | -$162.49K | — | -5.6% |
| Shareholder equity | $58.27M | $47.90M | $40.92M | $37.69M | — | +21.7% |
| Working capital | $42.33M | $36.96M | $30.77M | $26.50M | — | +14.5% |
| Net tangible assets | $44.20M | $37.09M | $30.44M | $26.58M | — | +19.2% |
| Shares issued | 169.92M | 168.93M | 170.78M | 173.19M | — | +0.6% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Capital expenditure | -$6.31M | -$3.07M | -$1.89M | -$2.21M | -105.3% |
| Investing cash flow | -$5.34M | -$2.24M | -$1.12M | -$1.68M | -137.8% |
| Share buybacks | -$3.04M | -$4.84M | -$3.59M | -$570.52K | +37.3% |
| Dividends paid | -$2.25M | — | — | — | — |
| Financing cash flow | -$3.95M | -$3.79M | -$3.22M | -$894.88K | -4.3% |
| Free cash flow | $2.20M | $8.40M | $3.90M | -$1.56M | -73.9% |
| End cash position | $34.78M | $35.56M | $30.12M | $28.68M | -2.2% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2025-06-30 | YoY |
|---|---|---|
| Cash & equivalents | $35.56M | |
| Cash & short-term investments | $35.56M | |
| Accounts receivable | $12.81M | |
| Total current assets | $50.30M | |
| Property, plant & equipment | $790.80K | |
| Goodwill & intangibles | $10.81M | |
| Total assets | $64.77M | |
| Total current liabilities | $13.34M | |
| Total debt | $469.92K | |
| Total liabilities | $16.88M | |
| Retained earnings | $5.76M | |
| Shareholder equity | $47.90M | |
| Working capital | $36.96M | |
| Net tangible assets | $37.09M | |
| Shares issued | 168.93M |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | 0.13 | 3 | $107.06M | +25.1% |
| Next year | 0.15 | 3 | $121.97M | +13.9% |
Analyst targets & ownership
Mean target$3.57
High target$3.70
Low target$3.44
Implied upside15.16%
Analyst count2
ConsensusSTRONG BUY
Strong buy / Buy1 / 2
Hold0
Sell / Strong sell0 / 0
Held by insiders40.99%
Held by institutions16.93%
Institutions holding16
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
2.83
+9.58% from price
SMA 20
2.68
+15.50% from price
SMA 50
2.72
+13.89% from price
SMA 100
2.59
+19.67% from price
SMA 200
2.45
+26.62% from price
EMA 12
2.83
+9.38% from price
EMA 26
2.75
+12.81% from price
EMA 50
2.69
+15.07% from price
RSI (14)
72.2
Overbought
MACD (12,26,9)
0.09
Hist 0.05
ATR (14)
0.13
4.33% of price
Realised vol 30D
42.1%
Annualised
Bollinger upper
3.05
20, 2σ
Bollinger lower
2.32
20, 2σ
50 / 200 cross
Golden
2.72 vs 2.45
Trend bias
Above 200
+26.62%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.09
Less volatile than market
Correlation to SPY
0.02
Largely independent
Realised vol 30D
42.1%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-29.5%
Peak to trough
Max drawdown 5Y
-67.9%
Peak to trough
ATR 14
0.13
4.33% of price
Beta (reported)
—
5Y monthly, from filing
Dividends & splits
Forward rate$0.04 / yr
Forward yield1.29%
5-year avg yield—
Payout ratio19.48%
Ex-dividend dateAug 21, 2026
Next pay date—
Last split1.006:1
Split dateAug 6, 2008
Headlines
Joe Milton III's best plays from 3-TD game vs. Cardinals Preseason Week 2
NFL Highlights · 9m ago
BioNTech (BNTX) Is Up 25.2% After First-in-Class Pumitamig Plus B7H3 ADC Lung Data – What's Changed
Simply Wall St. · 14m ago
Applied Industrial Technologies (AIT) Could Be 15% Undervalued After Earnings And 2027 Guidance
Simply Wall St. · 14m ago
Everpure (P) Lands Supply Agreement With A Second Top Five Hyperscaler
Simply Wall St. · 14m ago
Is Red Cat Holdings (RCAT) Quietly Recasting Its Identity From Drone Maker To Full Autonomy Platform?
Simply Wall St. · 14m ago
Darling Ingredients (DAR) Stock Looks Undervalued On Broader Checks Yet Fair On Earnings
Simply Wall St. · 14m ago
LifeMD (LFMD) Stock Sees Fair Value Cut After Analysts Lower Targets On Weaker Guidance
Simply Wall St. · 15m ago
Is Vivmark Residential (VMRK) Undervalued Following Its Index Exits And Financing Moves?
Simply Wall St. · 15m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.